The filing is an amendment (10-K/A) to the 2025 Annual Report primarily providing updated information on directors, executive compensation, and related-party transactions. As of June 30, 2025, the aggregate market value of common stock held by non-affiliates was approximately $4.63 million. As of March 20, 2026, there were 3,696,668 shares of common stock outstanding. The company maintains a board of five directors, three of whom are independent. The company disclosed various related-party transactions, including investments in Bionance LLC and a SPAC sponsor entity.